.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Citi
Queensland Health
Cerilliant
Fuji
Covington
Express Scripts
Argus Health
Daiichi Sankyo

Generated: December 14, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title:Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
Abstract: Glucopyranosyl-substituted benzene derivatives defined according to claim 1, including the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof. The compounds according to the invention are suitable for the treatment of metabolic disorders.
Inventor(s): Eckhardt; Matthias (Biberach, DE), Himmelsbach; Frank (Mittelbiberach, DE), Eickelmann; Peter (Mittelbiberach, DE), Thomas; Leo (Biberach, DE), Barsoumian; Edward Leon (Toyonaka, JP)
Assignee: Boehringer Ingelheim International GmbH (Ingelheim, DE)
Filing Date:Dec 15, 2005
Application Number:11/304,284
Claims:1. A glucopyranosyl-substituted benzene derivative selected from among: (1) 1-Methyl-2-(4-cyclopentyloxy-benzyl)-4-(.beta.-D-glucopyranos-1-yl)-b- enzene, (2) 1-Methyl-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-4-(.beta.-D-glucopyra- nos-1-yl)-benzene, (3) 1-Methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-4-(.beta.-D-glucopyra- nos-1-yl)-benzene, (4) 1-Methyl-2-(4-cyclohexyloxy-benzyl)-4-(.beta.-D-glucopyranos-1-yl)-benzen- e, (5) 1-Chloro-2-[4-(1-tert-butyloxycarbonylpiperidin-4-yloxy)-benzyl]-4-- (.beta.-D-glucopyranos-1-yl)-benzene, (6) 1-Chloro-2-[4-(piperdin-4-yloxy)-benzyl]-4-(.beta.-D-glucopyranos-1-yl)-b- enzene, (7) 1-Methoxy-2-(.beta.-D-glucopyranos-1-yl)-4-(4-ethynyl-benzyl)-benzene, (8) 1-Chloro-2-(4-methoxymethylethynyl-benzyl)-4-(.beta.-D-glucopyranos-1- -yl)-benzene, (9) 1-Chloro-2-(4-hydroxymethylethynyl-benzyl)-4-(.beta.-D-glucopyranos-1-yl)- -benzene, (10) 1-Chloro-2-(4-hydroxyethylethynyl-benzyl)-4-(.beta.-D-glucopyranos-1-yl)-- benzene, (11) 1-Ethynyl-2-(4-methoxy-benzyl)-4-(.beta.-D-glucopyranos-1-yl)-benzene, (12) 1-Methyl-2-(4-butyn-1-yl-benzyl)-4-(.beta.-D-glucopyranos-1-yl)-benz- ene, (13) 1-Chloro-2-(4-propyn-1-yl-benzyl)-4-(.beta.-D-glucopyranos-1-yl)- -benzene, (14) 1-Methyl-2-(4-propyn-1-yl-benzyl)-4-(.beta.-D-glucopyranos-1-yl)-benzene, (15) 1-Isopropyl-2-(4-ethynyl-benzyl)-4-(.beta.-D-glucopyranos-1-yl)-benz- ene, (16) 1-Chloro-2-(4-isopropylethynyl-benzyl)-4-(.beta.-D-glucopyranos-- 1-yl)-benzene, or a derivative thereof wherein one or more hydroxyl groups of the .beta.-D-glucopyranosyl group are acylated with groups selected from (C.sub.1-18-alkyl)carbonyl, (C.sub.1-18-alkyl)oxycarbonyl, phenylcarbonyl and phenyl-(C.sub.1-3-alkyl)-carbonyl, or a pharmaceutically acceptable salt thereof; including the tautomers, the stereoisomers thereof or the mixtures thereof, and salts thereof.

2. A glucopyranosyl-substituted benzene derivative according to claim 1 wherein the hydrogen atom of the hydroxyl group O-6 of the .beta.-D-glucopyranosyl-group is replaced by a group selected from among (C.sub.1-8-alkyl)carbonyl, (C.sub.1-8-alkyl) oxycarbonyl and phenylcarbonyl, or a pharmaceutically acceptable salt thereof.

3. A physiologically acceptable salt of the compounds according to claim 1 with inorganic or organic acids.

4. A pharmaceutical composition comprised of a compound according to claim 1 optionally together with one or more inert carriers and/or diluents.

5. A pharmaceutical composition comprised of a compound according to claim 1 or a physiologically acceptable salt thereof.

6. A method of treating conditions which can be influenced by inhibiting the sodium-dependent glucose cotransporter SGLT, said method comprised of the steps of administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1 or a physiologically acceptable salt thereof, wherein said conditions is selected from the group consisting of type 1 and type 2 diabetes mellitus, complications of diabetes, metabolic acidosis or ketosis, reactive hypoglycaemia, hyperinsulinaemia, glucose metabolic disorder, insulin resistance, metabolic syndrome, dyslipidaemias of different origins, atherosclerosis and related diseases, obesity, high blood pressure, chronic heart failure, oedema and hyperuricaemia.

7. A method of treating metabolic disorders said method comprised of the steps of administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1 or a physiologically acceptable salt thereof, wherein the metabolic disorder is selected from the group consisting of type 1 and type 2 diabetes mellitus, complications of diabetes, metabolic acidosis or ketosis, reactive hypoglycaemia, hyperinsulinaemia, glucose metabolic disorder, insulin resistance, metabolic syndrome, dyslipidaemias of different origins, atherosclerosis and related diseases, obesity, high blood pressure, chronic heart failure, oedema and hyperuricaemia.

8. A method of treating the degeneration of pancreatic beta cells and/or for improving the functionality of beta cells, said method comprised of the step of administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1 or a physiologically acceptable salt thereof.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Deloitte
Baxter
Boehringer Ingelheim
Colorcon
Chubb
McKinsey
UBS
Novartis
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot